Pramlintide
approvedAlso known as: Symlin, AC137
**Mechanism of Action** Pramlintide (Symlin, AC137) is a synthetic analog of human amylin, a neuroendocrine hormone co-secreted with insulin by pancreatic β-cells. It acts via amylin receptors in the area postrema and hypothalamus to regulate glucose homeostasis through three primary mechanisms: (1) slowing gastric emptying via vagal signaling, which delays postprandial glucose absorption; (2) suppressing glucagon secretion from α-cells, reducing hepatic glucose output; and (3) enhancing central satiety signaling, leading to reduced caloric intake. These effects complement insulin action by attenuating postprandial hyperglycemia and glycemic variability. **Key Research Findings** Clinical trials demonstrate that adjunctive pramlintide with mealtime insulin reduces HbA1c by 0.3–0.6% and body weight by 1–2 kg in type 1 and type 2 diabetes patients, compared to insulin alone. It also lowers postprandial glucose excursions by 30–50% and decreases daily insulin requirements by 10–20%. Common adverse effects include dose-dependent nausea (30–50% of patients), which typically resolves within 4 weeks, and an increased risk of severe hypoglycemia when insulin doses are not appropriately reduced. Long-term studies show sustained weight loss and improved glycemic control without tachyphylaxis. **Clinical Relevance** Pramlintide is FDA-approved as an adjunct to mealtime insulin for type 1 and type 2 diabetes inadequately controlled with insulin alone. It is particularly useful for patients with postprandial hyperglycemia, excessive glycemic variability, or weight gain from intensive insulin therapy. Dosing requires careful insulin reduction (by 30–50%) to mitigate hypoglycemia risk. Its utility is limited by gastrointestinal tolerability and the need for separate injections from insulin. For research purposes only — not medical advice.
Key data
C171H267N51O53S2Research & studies
Amylin is a glucoregulatory peptide hormone discovered in 1986.; Pramlintide, a human amylin analogue, was approved as an adjunct to insulin for type 1 and type 2 diabetes.; Recent interest has advanced several amylin-based therapies towards clinical use.; Amylin-based treatments show potential for cardiometabolic disease, including diabetes and obesity.
Pramlintide, an amylin mimetic, was FDA-approved in 2005 for type 1 and insulin-requiring type 2 diabetes and explored for obesity, but development stalled due to dosage, safety, and formulation issues.; Advances in peptide chemistry have reinvigorated amylin-based therapeutics, with new molecules on the cusp of approval.; GLP1 receptor agonist-based therapies raise concerns about loss of lean body mass.; Widespread pharmacotherapy of otherwise healthy populations with overweight or obesity requires further regulatory and ethical consideration.
Amylin deficiency in diabetes contributes to postprandial hyperglycemia; its actions include suppressing glucagon, delaying gastric emptying, and promoting satiety.; Pramlintide, the only approved amylin analog, enhances glycemic control in T1D and T2D without increasing hypoglycemia or weight gain.; Novel strategies include PEGylation, oral formulations, and combination therapies (e.g., CagriSema with GLP-1 agonists) to improve efficacy and patient convenience.; Amylin-based therapies may enable precision medicine by targeting multiple hormonal imbalances beyond the T1D/T2D classification.
Insulin resistance in T1D is distinct from type 2 diabetes and involves complex metabolic and autoimmune mechanisms.; Insulin treatment itself may contribute to insulin resistance through glucolipotoxicity, hyperinsulinemia, and oxidative stress.; Insulin resistance interacts with endothelial dysfunction to worsen diabetes-related complications.; Continuous subcutaneous insulin infusion can improve insulin resistance, but other agents like metformin or GLP-1 agonists are not widely used due to cost and off-label concerns.
Pramlintide demonstrated weight loss exceeding 3% in clinical trials without major untoward effects.; Cagrilintide achieved weight loss of more than 10% in early trials, but with more frequent nausea compared to pramlintide.; Amylin analogs are effective compared to glucagon-like peptide 1 receptor agonists.; Future research may focus on combining amylin analogs with other weight-loss drugs, such as dual and triple incretin-based co-agonists.
Amylin inhibits homeostatic and hedonic feeding, induces satiety, and decreases body weight.; Pramlintide is a recombinant analog of human amylin used with insulin for diabetes therapy.; Pramlintide has not been linked to serum enzyme elevations or clinically apparent liver injury.
Frequently asked questions
What is Pramlintide?
**Mechanism of Action** Pramlintide (Symlin, AC137) is a synthetic analog of human amylin, a neuroendocrine hormone co-secreted with insulin by pancreatic β-cells. It acts via amylin receptors in the area postrema and hypothalamus to regulate glucose homeostasis through three primary mechanisms: (1) slowing gastric emp
How does Pramlintide work?
Amylin analog adjunct to insulin that slows gastric emptying, suppresses glucagon, and increases satiety.
What is the research status of Pramlintide?
Pramlintide is currently classified as approved, with 443 research references on record. This is for research purposes only and is not medical advice.
What is the molecular weight of Pramlintide?
Pramlintide has a molecular weight of approximately 3949 g/mol (formula C171H267N51O53S2).
Related peptides
Once-daily acylated GLP-1 receptor agonist for type 2 diabetes and chronic weight management.
Long-acting GLP-1 receptor agonist that improves glycemic control, slows gastric emptying, and reduces appetite.
Exendin-4-based GLP-1 receptor agonist from Gila monster venom; first-in-class incretin mimetic.
Dual GIP/GLP-1 receptor agonist delivering potent glucose lowering and weight reduction.
Once-weekly GLP-1 receptor agonist fused to an IgG4 Fc fragment for extended half-life.
Short-acting exendin-4-based GLP-1 receptor agonist with pronounced gastric-emptying delay.
Build on Pramlintide data programmatically
Structured peptide data, semantic search, and AI summaries via one API.
Get a free API key